Can a bone drug stop smoldering myeloma in its tracks?
NCT ID NCT03839459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether denosumab, a drug usually used for bone health, could safely reduce the risk of smoldering multiple myeloma turning into active multiple myeloma. Twenty people with smoldering multiple myeloma took part. The goal was to see if the drug could lower their risk category and prevent bone problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?
- New blood test screening targets hidden cancer in black communities
- New antibody shows promise in slowing early myeloma
- 1,000 volunteers help scientists unlock the mystery of myeloma progression
- Can a cancer drug stop myeloma before it starts?
- New italian network aims to catch rare blood disease earlier